COMBINATION THERAPIES USING HDAC INHIBITORS

摘要

The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, chlorambucil, wherein the first and second amounts or doses together comprise a therapeutically effective amount.